{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:56:34Z","timestamp":1770998194024,"version":"3.50.1"},"reference-count":12,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,10,11]],"date-time":"2012-10-11T00:00:00Z","timestamp":1349913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>A consensus conference conducted by the Medical and Scientific Advisory Council of the National Hemophilia Foundation was held in New Orleans, <jats:styled-content style=\"fixed-case\">LA<\/jats:styled-content>, on November 11, 2010, to discuss the impediments to conducting clinical research in persons with haemophilia, von Willebrand's disease and rare bleeding disorders. The conference combined presentations providing academic, non\u2010profit and industry perspectives with periods of open discussion. The objective of this conference was to identify the many challenges involved in facilitating U.S. Food and Drug Administration approval of innovative products for these patient populations.<\/jats:p>","DOI":"10.1111\/hae.12035","type":"journal-article","created":{"date-parts":[[2012,10,11]],"date-time":"2012-10-11T14:05:43Z","timestamp":1349964343000},"page":"188-193","source":"Crossref","is-referenced-by-count":2,"title":["MASAC Consensus Conference: impediments to conducting clinical research in persons with haemophilia, von Willebrand's disease and rare bleeding disorders"],"prefix":"10.1111","volume":"19","author":[{"given":"M. A.","family":"Koerper","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology UCSF School of Medicine San Francisco CA USA"},{"name":"National Hemophilia Foundation New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Frick","sequence":"additional","affiliation":[{"name":"National Hemophilia Foundation New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. M.","family":"Kessler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Coagulation Georgetown University Washington DC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,10,11]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"17","article-title":"International ethical guidelines for biomedical research involving human subjects","volume":"182","author":"Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization","year":"2002","journal-title":"Bull Med Ethics"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(02)02480-7"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/381709"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17679-4"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25694"},{"key":"e_1_2_7_7_1","unstructured":"FDA Information Sheet: Guidance for Institutional Review Boards and Clinical Investigators.Payment to Research Subjects. 1998 update. Available athttp:\/\/www.fda.gov\/RegulatoryInformation\/Guidances\/ucm126429.htm. Accessed June 25 2012."},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2003.64"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01258.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-0082"},{"key":"e_1_2_7_11_1","volume-title":"Operational Procedures for the Gene Therapy Advisory Committee in its Role as the National Ethics Committee for Gene Therapy Clinical Trials and Those with Products Derived from Stem Cell Lines","author":"Gene Therapy Advisory Committee","year":"2008"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02822.x"},{"key":"e_1_2_7_13_1","unstructured":"U.S. Department of Health and Human Services Health Resources and Services Administration.Pharmacy Affairs & 340B Drug Pricing Program. Introduction to 340B Drug Pricing Program. Available athttp:\/\/www.hrsa.gov\/opa\/introduction.htm. Accessed June 25 2012."}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.12035","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T06:24:24Z","timestamp":1698647064000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.12035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,11]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1111\/hae.12035"],"URL":"https:\/\/doi.org\/10.1111\/hae.12035","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,11]]}}}